EI
ANIK icon

EAM Investors’s Anika Therapeutics ANIK Stock Holding History

EAM Investors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,783
Closed -$1.28M – 299
2016
Q2 		$1.28M Sell
23,783
-1,363
-5% -$64.2K 0.19% 217
2016
Q1 		$1.13M Buy
+25,146
New +$1.02M 0.18% 218
2014
Q3 		– Sell
-22,245
Closed -$1.03M – 313
2014
Q2 		$1.03M Sell
22,245
-10,670
-32% -$475K 0.2% 291
2014
Q1 		$1.35M Sell
32,915
-5,040
-13% -$187K 0.24% 197
2013
Q4 		$1.45M Sell
37,955
-45
-0.1% -$1.39K 0.26% 158
2013
Q3 		$910K Buy
+38,000
New +$853K 0.18% 295

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

EAM Investors's ANIK Position: Q3 2016 in Review

EAM Investors sold out of Anika Therapeutics (ANIK) in Q3 2016, closing a stake of 23,783 shares — an estimated $1.28M sold.

EAM Investors first reported a position in ANIK in Q3 2013 and held it in 6 quarters. The position peaked at $1.45M in Q4 2013. 163 funds tracked by Wall St. Rank hold ANIK as of Q3 2016.

  • EAM Investors reported no remaining Anika Therapeutics position as of Q3 2016 after selling out during the quarter.
  • EAM Investors sold 23,783 Anika Therapeutics shares in Q3 2016, an estimated $1.28M.
  • EAM Investors first reported a position in Anika Therapeutics in Q3 2013 and held it in 6 quarters.
  • EAM Investors's Anika Therapeutics position peaked at $1.45M in Q4 2013.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2016.

Based on EAM Investors's 13F filing for Q3 2016, filed 10 Nov 2016.